Document is current
Any future updates will be listed below
-
Authors
Janssen, Joost https://orcid.org/0000-0001-7613-2067
Guil Gallego, Ana
Díaz-Caneja, Covadonga Martínez https://orcid.org/0000-0001-8538-3175
Gonzalez Lois, Noemi
Janssen, Niels
González-Peñas, Javier https://orcid.org/0000-0002-3850-3012
Macias Gordaliza, Pedro https://orcid.org/0000-0001-5305-3104
Buimer, Elizabeth
van Haren, Neeltje
Arango, Celso https://orcid.org/0000-0003-3382-4754
Kahn, René https://orcid.org/0000-0001-5909-8004
Pol, Hilleke E. Hulshoff
Schnack, Hugo G.
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI22/01621)
- License Information
-
More Information
Article History
Received: 19 August 2024
Accepted: 31 March 2025
First Online: 24 April 2025
Competing interests
: Dr. Díaz-Caneja has received honoraria from Angelini and Viatris. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen-Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering-Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda. Dr. Cahn has received unrestricted research grants from or served as an independent symposium speaker or consultant for Eli Lilly, Bristol-Myers Squibb, Lundbeck, Sanofi-Aventis, Janssen-Cilag, AstraZeneca, and Schering-Plough. The other authors report no financial relationships with commercial interests.
